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HV, especially HBV and HCV, and it seems to be related to the
pathogenicity of cirrhosis and fulminant hepatic failure.
PP-109 Usefulness of the serum concentrations of
TIMP-1 and TIMP-2 for predicting liver ﬁbrosis in
patients with chronic hepatitis B
R.T. Gao1, C.L. Zhu1 *, Y. Li1, Z.H. Zhao1. 1Department
of Infectious Disease, Anhui Provincial Hospital, Anhui
Medical University, Hefei, China
Objectives: We determined whether serum concentration
of TIMP-1 and TIMP-2 are related to the progress of liver
ﬁbrosis in patients with chronic hepatitis B (CHB).
Methods: Commercially available ELISA were used to
study circulating values of TIMP-1 and TIMP-2 in
CHB patients (n = 159) and 20 healthy controls. TIMP-1
and TIMP-2 expressions in the liver were detected
by immunohistochemical staining, then analyzed the
correlation between the levels of hepatic expression
and serum concentration of them. Hepatic histology was
evaluated, and quantiﬁed the stage of ﬁbrosis by using the
Hepatitis-Activity-Index (HAI) according to Ishak et al.
Results: The serum concentration of TIMP-1 or TMIP-2
positively correlated with their expression in the liver
of CHB patients, and both of them were higher in
the patients than those in the healthy controls, and
which had a signiﬁcant difference (P < 0.05). The serum
concentrations of TIMP-1 and TIMP-2 increased signiﬁcantly
with development of ﬁbrosis and had positive correlations
with HAI (r = 0.51, P < 0.01; r = 0.42, P < 0.01), whereas serum
ALT wasn’t related to ﬁbrosis or HAI.
Conclusions: Regular determinations of both TIMP-1 and
TIMP-2 in CHB patients may be used as indicators of
increasing ﬁbrosis.
Figure 1. Correlation between TIMP-1 and -2 expressions in
the liver and their concentration in the serum of patients
with CHB.
Table 1. The serum concentration of TIMP-1 and -2 in CHB patients with
different stages of ﬁbrosis
TIMP-1 (mg/L) TIMP-2 (mg/L) ALT (IU/L)
S0 84.32±18.53 52.34±24.21 45.37±9.31
S1 109.32±14.67 108.96±12.56 105.54±8.59
S2 135.65±22.95 111.47±25.32 676.4±202.35
S3 181.05±39.44 178.28±17.76 432.2±273.88
S4 279.91±61.83 255.54±110.02 75.7±29.80
PP-110 A study of the carriers of hepatitis B surface
antigen among patients with schistosomal
hepatic ﬁbrosis
S. Zaki1 *, A. Abd El Moety2, R. Zaher2, M. Abou Khatwa1.
1Microbiology, Faculty of Medicine Alexandria University,
2Internal Medicine, Faculty of Medicine, Alexandria
University, Egypt
Introduction: Hepatitis B virus infection is recognized as
a major public health problem causing acute, persistant
or chronic liver infection. In Egypt, hepatitis B virus
infection is considered to be endemic. The attack rate of
hepatitis B was estimated to reach 8.9/10,000 in Alexandria.
Schistosomiasis is considered the major health problem in
Egypt. 12 14 million people are infected with Schistosoma
mansoni.
When Schistosomal and non-Schistosomal patients were
exposed to HBV, they were found to be equally susceptible,
however follow-up studies claimed that the ﬁrst group of
patients tend to exhibit hepatitis B antigenemia for longer
periods than the second group and this may hugely increase
the reservoir of carriers.
Aim: Determine the prevalence of HBsAg carriers,
demonstration of routes of antigen excretion and its
presence in liver sections and the prevalent subtype.
Subjects and Methods: Forty carriers of the hepatitis B
surface antigen were selected from 539 cases of
Schistosomal hepatic ﬁbrosis:
A. Detection of HBsAg in patients sera, Saliva, Urine and
Stools & Anti-HBcAg IgM.
B. Demonstration of HBsAg in infected hepatocytes.
C. Subtyping of HBsAg using the counter immuno-
electrophoresis.
Results:
• Hepatitis B surface antigen carriers was7.42%, Anti-HBsAg
IgM was negative.
• 5% of the salivary samples were HBsAg positive, while 50%
of the Urine and Stool were HBsAg positive.
• Urine and Saliva positivity ran parallel.
• Stool samples positive for HBsAg were all positive for
occult blood.
• Subtyping of the HBsAg for showed the “ay” subspeciﬁcity
which is considered the constant type of North Africa.
Conclusions:
• Screening of Schistosomal patients for the HBs antigen is
of importance as they represent a highly disseminating
source of infection.
• “ay” is the predominant subtype of HBs Ag.
• Disinfection of secretions and excretions of HBsAg positive
patients and their utensils is essential.
PP-111 Optimal threshold: baseline serum hepatitis B
virus DNA and alanine transaminase levels
predict the 2-year on-treatment virological
response to lamivudine
J. Yan1 *, W. Xie1, Q. Wang2, Y. Li1, X. Feng2, J. Cheng1,2.
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Aims: To evaluate the predictive value of baseline levels of
HBVDNA and ALT for the long term efﬁcacy of lamivudine
treatment for patients with chronic hepatitis B and
determine the optimal cut off values of baseline levels
of HBVDNA and ALT.
Methods: A total of 163 HBeAg-positive chronic hepatitis B
patients receiving LAM treatment were recruited into the
present study. Logistic regression analysis was performed
to screen independent predictors of 2-year on-treatment
virological response among the baseline parameters. The
ROC curve was used to evaluate the predictive value of
these independent predictors. The accuracy of prediction
was assessed using area under curve (AUC) and optimal cut
off values were determined through maximizing Youden’s
index.
Results: After 2 years of LAM treatment, HBVDNA was
undetectable in 114 (69.9%) patients and LAM related
resistance mutation was detectable in 45 (27.6%) patients.
Logistic regression analysis indicated the baseline levels
of ALT and HBVDNA were the independent predictors
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of efﬁcacy. ROC curve analysis suggested the integration
parameter derived from baseline levels of ALT and HBVDNA
had the maximal predictive value for the 2-year on-
treatment virological response, with the AUC of 0.869. The
optimal cut off values of ALT and HBVDNA were 220U/L
and 8.2 log10 copies/ml, respectively. After 2 years of
LAM treatment, the possibility of on-treatment virological
response in the patients was 95.5% when the baseline level
of ALT was greater than 220U/L and that of HBVDNA was
less than 8.2 log10 copies/ml.
Conclusion: The incidence of LAM-resistant mutations in
HBeAg-positive CHB patients may be markedly reduced and
long term efﬁcacy be improved when the baseline level of
ALT was greater than 220U/L and that of HBVDNA was less
than 8.2 log10 copies/ml.
PP-112 Hepatitis B vaccination status of health care
workers at a tertiary care hospital in Multan
N. Jadoon1 *, A. Shahzad1, R. Yaqoob1, A. Raza1, I. Hussain1.
1Nishtar Medical College Hospital, Multan, Pakistan
Objective: To determine the hepatitis B vaccination status
of health care workers (HCWs) at a tertiary care hospital in
Multan.
Methods: This descriptive, cross-sectional interview based
study was carried out in Nishtar Medical College
Hospital Multan from January 2009 to March 2009.
Structured questionnaires were distributed among 200
health care workers after taking verbal consent. The
questionnaire included demographic information, screening
and vaccination status regarding hepatitis B and related
data. Data analysis was done using SPSS v.15.
Results: Out of the total 174 HCWs who returned
questionnaire, there were 68 doctors, 32 ﬁnal year students,
36 nurses, 23 operation theater/laboratory technicians and
15 sanitary workers. The mean age of study group was
31.68±3.95 years. 80.46% of the HCWs had undergone
screening for Hepatitis B. Though 93.11% of the HCWs
thought they were at risk because of their occupation, only
62.07% were completely vaccinated, 12.64% were partially
vaccinated while 25.29% were not vaccinated against
hepatitis B. Among those who were vaccinated, only 12.64%
had checked post vaccination antibody status. Almost all
the HCWs interviewed (96.56%) thought that vaccination
can prevent hepatitis B. The most commonly cited reasons
for non-vaccination were forgetting dosage schedule, lack of
awareness, laziness and negligence respectively. An ample
number (78.16%) of the HCWs were aware of the safe
practices for preventing transmission of infection.
Conclusion: The results show that a substantial proportion
of HCWs are not vaccinated against Hepatitis B. It is
recommended that all the HCWs should be vaccinated for
Hepatitis B and their Anti-HBs levels should be determined,
and in case they are not satisfactory, revaccination must
be considered to prevent occupation related infection gain
and dissemination.
PP-113 Enhanced growth of L02 cells by the hepatitis B
virus X protein is associated with activation of
Notch signaling
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and Hepatology, Tongji Hospital, Tongji Medical College,
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Objectives: This study aimed to investigate the oncogenic
effects of Hepatitis B virus X protein (HBx) and its
relationship with Notch signaling in human non-tumour
hepatic cell line L02 cells.
Methods: The HBx gene was introduced into L02 cells
by transfection with vectors stablely expressing HBx.
The cell growth, cell cycle, apoptosis and xenograft
BALB/c nude mice tumor model of cells were studied.
Using Western blot analysis and quantitative real-
time RT-PCR, the expression levels of Notch signaling
components were also investigated. Blocking Notch signaling
with a g-Secretase inhibitor N-[N-(3,5-diﬂuorophenacetyl)-
l-alanyl]-S-phenylglycine t-butyl ester (DAPT), the cell
growth, cell cycle and apoptosis of cells were analysed
again.
Results: HBx strongly stimulated cell growth, promoted cell
cycle progression and inhibited apoptosis of L02 cells. In
addition, HBx accelerated tumor formation of L02 cells
in BALB/c nude mice. Upregulated expression of Notch
signalig components were observed in stably HBx-expressing
L02 cells. While Notch signaling was blocked by DAPT, the
stimulation of cell growth, the promotion of cell cycle
progression and the inhibition of apoptosis were partially
attenuated in HBx-expressing L02 cells in a dose and
time dependent manner. But Normal L02 cells were not
signiﬁcantly affected by Notch signaling blocking.
Conclusions: Our studies demonstrate that HBx can
signiﬁcantly promote the growth of human non-tumour
hepatic cell line L02 cells both in vitro and in vivo, which
may function through the activation of Notch signaling
pathway. This will deﬁne a novel role of HBx in HCC
progression and implicate the Notch signaling as a potential
therapeutic target.
PP-114 Celiac disease: the top of an iceberg in patients
with hepatitis?
A. Hekmatdoost1 *, H. Sima1. 1RIGLD, Tehran, Iran
Introduction: Celiac disease has been associated with
other autoimmune disorders such as autoimmune hepatitis,
moreover it is known that T cell mediated immune
response to dietary gluten and released cytokines are
important for the entheropathy seen in celiac disease.
We investigated celiac autoantibodies in patients with
autoimmune hepatitis (AIH), and chronic hepatitis B (CHB).
Methods: Sera from 84 patients with Autoimmune
Hepatitis (AIH) type 1 and 88 patients with Chronic
Hepatitis B (CHB) were tested for Immunoglobulin A and G
antibodies to Gliadin, Immunoglobulin A antibodies to
tissue transglutaminase using enzyme immunoassay, and
Immunoglobulin A anti-endomysial antibodies by both
indirect immunoﬂuorescence, and enzyme immunoassay.
The patients positive for anti-endomysial antibodies and/or
anti tissue transglutaminase antibodies were considered for
duodenal biopsy.
Results: Immunoglobulin A anti-endomysial and Im-
munoglobulin A anti-gliadin antibodies were positive in two
of 84 patients with AIH. Moreover, Immunoglobulin A anti-
gliadin antibodies were positive in another patient who was
also positive for anti tissue transglutaminase antibodies.
Tissue transglutaminase antibodies were positive in
eight (9.1%) of 88 patients with CHB, two of which were also
positive for anti-endomysial antibodies. One of the patients
with CHB was only positive for anti-endomysial antibodies.
Discussion: Compared with the normal population, the
prevalence of celiac autoantibodies in CHB and AIH patients
is relatively high, and it is noteworthy that most positive
patients are asymptomatic for celiac disease. We suggest
screening for celiac disease before and during treatment in
patients with viral and autoimmune hepatitis.
